MediciNova Inc.

06/08/2022 | Press release | Distributed by Public on 06/08/2022 04:38

MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome